Enquest (ENQ) Gets a Buy from Canaccord Genuity
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
According to TipRanks, Sharp is a 5-star analyst with an average return of 24.5% and a 53.21% success rate. Sharp covers the Energy sector, focusing on stocks such as Arrow Exploration Corp, Vaalco Energy, and Nostrum Oil & Gas.
Enquest has an analyst consensus of Moderate Buy, with a price target consensus of p16.00.
Based on Enquest's latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of p594.69 million and a net profit of p63.43 million. In comparison, last year the company earned a revenue of p717.06 million and had a GAAP net loss of p9.62 million
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 hours ago
- Yahoo
Metallic Minerals Closes C$6 Million Brokered Private Placement Financing
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC / / July 30, 2025 / Metallic Minerals Corp. (TSX-V:MMG)(OTCQB:MMNGF)(FSE:9MM1) (the "Company" or "Metallic") is pleased to announce that it has completed its previously announced brokered private placement financing (the "Offering"), including the exercise in full of the over-allotment option, for total gross proceeds of C$6,000,024 from the sale of 25,000,100 units of the Company (each, a "Unit") at a price of C$0.24 per Unit. Each Unit consists of one common share of the Company (each, a "Common Share") and one-half of one common share purchase warrant of the Company (each whole warrant, a "Warrant"). Each Warrant entitles the holder to purchase one Common Share at a price of C$0.34 at any time on or before July 30, 2027. Cormark Securities Inc., as lead agent, and Canaccord Genuity Corp., SCP Resource Finance LP, and Beacon Securities Limited, acted as agents in connection with the Offering (collectively, the "Agents"). The Units were sold in Canada in accordance with the listed issuer financing exemption under National Instrument 45-106 - Prospectus Exemptions, as amended by Coordinated Blanket Order 45-935 - Exemptions from Certain Conditions of the Listed Issuer Financing Exemption. The Common Shares and Warrants are freely tradeable in Canada in accordance with applicable Canadian securities legislation. The Units were also sold in the United States pursuant to one or more exemptions from the registration requirements of the United States Securities Act of 1933, as amended(the "U.S. Securities Act") and in offshore jurisdictions in accordance with applicable securities legislation. There is an offering document related to the Offering that can be accessed under the Company's profile at and on the Company's website at: (the "Offering Document"). The Company intends to use the net proceeds of the Offering to advance its La Plata copper-silver-gold-PGE project located in southwestern Colorado, USA, exploration at its Keno Silver project and other properties in Yukon, Canada, and for working capital and general corporate purposes, as described further in the Offering Document. Newmont Corporation, through its wholly-owned subsidiary, Newcrest International Pty Ltd., ("Newmont") has indicated that it intends to exercise its participation rights pursuant to the investor rights agreement with the Company dated May 18, 2023, to maintain its pro rata shareholding in the Company in connection with the Offering. No commission or other fees will be made to the Agents in connection with any participation by Newmont. To accommodate participation by management and insiders, along with the anticipated participation of Newmont (an insider of the Company), a separate non-brokered private placement is expected to follow which shall constitute a related party transaction pursuant to Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101"). The Company is exempt from the requirements to obtain a formal valuation and minority shareholder approval in connection with the participation of the related parties in the private placements in reliance on the exemptions contained in sections 5.5(b) and 5.7(1)(a) of MI 61-101, respectively. The Company did not file a material change report at least 21 days before the expected closing date of the Offering as the insider participation had not been confirmed at that time and the Company wished to close the Offering as expeditiously as possible. Any securities issued to the foregoing management and insiders under the current Offering or the subsequent private placement will be subject to a hold period expiring four months and one day following the issue date. As consideration for their services under the Offering, the Agents received aggregate cash fees of C$247,530.24 and were issued at total of 1,031,375 non-transferable broker warrants of the Company (the "Broker Warrants"). Each Broker Warrant is exercisable into one Common Share at a price of C$0.34 per Common Share at any time on or before July 30, 2027. In connection with the Offering, the Company has also paid finder's fees totaling $29,000 to certain finders other than the Agents. This news release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful, including any of the securities in the United States of America. The securities have not been, and will not be, registered under the United States Securities Act of 1933, as amended or any U.S. state securities laws, and may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons, absent registration or any applicable exemption from the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. About Metallic Minerals Corp. Metallic Minerals Corp. is a resource-stage mineral exploration company, focused on copper, silver, gold, platinum group elements, and other critical minerals at the La Plata project in southwestern Colorado and the Keno Silver project adjacent to Hecla Mining's Keno Hill silver operations in the Yukon Territory. The Company is also one of the largest holders of alluvial gold claims in the Yukon and is building a production royalty business by partnering with experienced mining operators. Metallic Minerals is led by a team with a track record of discovery and exploration success on several major precious and base metal deposits in North America, as well as having large-scale development, permitting and project financing expertise. The Metallic Minerals team is committed to responsible and sustainable resource development and has worked closely with Canadian First Nation groups, U.S. Tribal and Native Corporations, and local communities to support successful project development. FOR FURTHER INFORMATION, PLEASE CONTACT: and info@ Phone: 604-629-7800Toll Free: 1-888-570-4420 Forward-Looking Statements This news release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts including, without limitation, statements regarding potential mineralization, title, expected results of operations, as well as financial position, prospects, and future plans and objectives of the Company are forward-looking statements that involve various risks and uncertainties. Although Metallic Minerals believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Forward-looking statements are based on a number of material factors and assumptions. Factors that could cause actual results to differ materially from those in forward-looking statements include failure to obtain necessary approvals, changes in project parameters as plans continue to be refined, results of future resource estimates, future metal prices, availability of capital and financing on acceptable terms, general economic, market or business conditions, risks associated with regulatory changes, defects in title, availability of personnel, materials and equipment on a timely basis, accidents or equipment breakdowns, uninsured risks, unanticipated environmental impacts on operations and costs to remedy same and other exploration or other risks detailed herein and from time to time in the filings made by the Company with securities regulators. Readers are cautioned that mineral resources that are not mineral reserves do not have demonstrated economic viability. Mineral exploration, development of mines and mining operations is an inherently risky business. Accordingly, the actual events may differ materially from those projected in the forward-looking statements. For more information on Metallic Minerals and the risks and challenges of their businesses, investors should review their annual filings that are available at Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. SOURCE: Metallic Minerals Corp. View the original press release on ACCESS Newswire
Yahoo
8 hours ago
- Yahoo
Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference
NEEDHAM, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that Paul Peter Tak, M.D., Ph.D., FMedSci, Candel's President and Chief Executive Officer, will present at the Canaccord Genuity 45th Annual Growth Conference, being held on August 12-14, 2025 in Boston, MA. Date: Wednesday, August 13, 2025Time: 2:00-2:25PM ESTWebcast Link: Canaccord Genuity / Candel Presentation A webcast of the presentation will be available by selecting Events and Presentations under the News & Events tab in the Investors section on A replay of the webcast will be archived for up to 90 days following the session date. About Candel Therapeutics Candel is a clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform. The Company recently completed successful phase 2a clinical trials of CAN-2409 in non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC), and a pivotal, placebo-controlled phase 3 clinical trial of CAN-2409 in localized prostate cancer, conducted under a Special Protocol Assessment (SPA) agreed with the U.S. Food and Drug Administration (FDA). In May 2025, the FDA granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CAN-2409 for the treatment of newly diagnosed localized prostate cancer in patients with intermediate-to-high-risk disease. CAN-3110 is the lead product candidate from the HSV platform and is currently in an ongoing phase 1b clinical trial in recurrent high-grade glioma (rHGG). Initial results were published in Nature and CAN-3110 received Fast Track Designation and Orphan Drug Designation from the FDA. Finally, Candel's enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. For more information about Candel, visit: Forward-Looking Statements This press release includes certain disclosures that contain 'forward-looking statements,' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the timing and advancement of current and future development programs; expectations regarding the therapeutic benefit of the Company's platforms; and expectations regarding the potential benefits conferred by Regenerative Medicine Advanced Therapy Designation, Fast Track Designation, Orphan Drug Designation or Orphan Designation. The words 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'plan,' 'anticipate,' 'intend,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'target' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of development programs; expectations regarding the therapeutic benefit of the Company's programs; that final data from the Company's preclinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; the Company's ability to efficiently discover and develop product candidates; the Company's ability to obtain and maintain regulatory approval of product candidates; the Company's ability to maintain its intellectual property; the implementation of the Company's business model, including strategic plans for the Company's business and product candidates; and other risks identified in the Company's filings with the U.S. Securities and Exchange Commission (SEC), including the Company's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, each as filed with the SEC and any subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Company's views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Investor ContactTheodore JenkinsVice President, Investor Relations and Business DevelopmentCandel Therapeutics, Media ContactBen ShannonVice PresidentICR Healthcare CandelPR@ produjo un error al recuperar la información Inicia sesión para acceder a tu portafolio Se produjo un error al recuperar la información Se produjo un error al recuperar la información Se produjo un error al recuperar la información Se produjo un error al recuperar la información
Business Insider
11 hours ago
- Business Insider
'PC Shipments are Forecast To Rise…,' Intel Stock (NASDAQ:INTC) Slips
Chip stock Intel (INTC) recently put up its earnings report, and one key point emerged that proved oddly welcome. As it turns out, Intel's work to help augment the artificial intelligence (AI) PC market has done Intel quite a bit of good. This serves as a bright spot for Intel, which is in desperate need of those as so much of the market seems to be turning on it. But shareholders were still clearly skeptical, and shares slipped modestly in Tuesday afternoon's trading. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. One of the biggest surprises to emerge from Intel's recent earnings report was the revelation that Intel is a major part of the AI PC market. In fact, three key PC makers—HP (HPQ), Lenovo (LNVGY), and Dell (DELL) —all turned to Intel for its line of Core Ultra processors that can handle AI operations. Given that those three firms represent around 66% of the global PC market, Intel may have landed a serious win. There was further help from Gartner Research Principal Rishi Padhi, who noted that PC shipments '…are forecast to rise 2.4% in 2025, propelled by a tariff-driven front-loaded inventory surge in the first half of 2025 in the U.S., and ongoing Windows 11 replacement cycles.' That is also good news for Intel. With foundry shipments up 4.4% on a year-over-year basis, there are some signs of a comeback in the making for Intel, though perhaps a slow one, and one not quite as pronounced as some might like. A Surprising Blow to Costa Rica Intel has been closing down operations worldwide, and one more such operation emerged recently. Intel announced plans to shut down chip assembly and test plant operations in Costa Rica, a move which will, somehow, '…drive greater efficiency and utilization within our global manufacturing network.' However, that is not the end of Intel in Costa Rica. Its engineering and corporate service positions will remain untouched, at least for now, reports note. Intel plans to absorb the losses by consolidating Assembly and Test Manufacturing (ATM) operations in Vietnam and Malaysia instead. Interestingly, some elements in Costa Rica moved quickly following the announcement. The Association of Free Zone Companies of Costa Rica (AZOFRAS) called on Costa Rican leaders to '…take swift action to safeguard national competitiveness,' one report noted. Is Intel a Buy, Hold or Sell? Turning to Wall Street, analysts have a Hold consensus rating on INTC stock based on one Buy, 25 Holds and three Sells assigned in the past three months, as indicated by the graphic below. After a 31.36% loss in its share price over the past year, the average INTC price target of $22.25 per share implies 8.75% upside potential.
